Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epirubicin for Sepsis and Septic Shock
NCT05033808Phase 2Recruiting
- Sponsor
- Universitätsklinikum Jena
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of epirubicin in sepsis, septic shock, sponsored by Universitätsklinikum Jena. Started Oct 2022; status: recruiting.
02
Drugs
epirubicin
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT05033808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033808.